Frontlight ResearchEarly access
Sickle cell disease trials in United States
99 of 133 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleLet's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
- Where
- St Louis
- Age
- 8 years and over
- People
- 60
- Run by
- Washington University School of Medicine
See details and how to joinNCT06689800 - Phase 1Taking peopleA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Where
- Atlanta, Augusta, Birmingham, Chicago, Cincinnati, Durham, Greenville, Indianapolis, New York, Pittsburgh, San Francisco
- Age
- 18 years and over
- People
- 24
- Run by
- Disc Medicine, Inc
See details and how to joinNCT07187973 - Phase 2Taking peopleHaploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
- Where
- Memphis
- Age
- Up to 22 years
- People
- 45
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT07616154 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Where
- Augusta, Baltimore, Birmingham, Chicago, Easton, Flowood, Greenville, Houston, Jacksonville, Louisville, Orange, Philadelphia, Riverdale, The Bronx, Washington D.C., Winston-Salem
- Age
- 12 years to 100 years
- People
- 354 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06439082 - No phaseNot yet taking people in United StatesMechanisms Within the Autonomic Nervous SysTEm undeRlying MusIc Therapy's aNalgesic Effects in Sickle Cell Disease (MASTERMIND)
- Where
- Cleveland
- Age
- 18 years and over
- People
- 10
- Run by
- University Hospitals Cleveland Medical Center
See details and how to joinNCT07928089 - Phase 1Taking peopleStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
- Where
- Bethesda
- Age
- 18 years to 65 years
- People
- 35
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT05904093 - Phase 4Taking peopleClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
- Where
- Atlanta, Philadelphia
- Age
- 18 years to 50 years
- People
- 65
- Run by
- University of Pennsylvania
See details and how to joinNCT06665997 - Phase 1Not yet taking people in United StatesBuprenorphine for the Management of Pain in Children With Sickle Cell Disease
- Where
- Boston
- Age
- 12 years to 22 years
- People
- 25
- Run by
- Natasha Archer
See details and how to joinNCT07799571 - Phase 2Taking peopleSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Where
- Atlanta, Bethesda, Boston, Columbus, Flowood, Hollywood, Houston, Jamaica, Little Rock, Minneapolis, New York, Orange, Richmond, The Bronx
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00 - No phaseNot yet taking people in United StatesHypoxic Red Blood Cells in Sickle Cell Anemia
- Where
- Atlanta, Baltimore, Chicago, Farmington, Pittsburgh
- Age
- 7 years and over
- People
- 48
- Run by
- Hemanext
See details and how to joinNCT06743113 - No phaseNot yet taking people in United StatesFocused Ultrasound Neuromodulation for Chronic Pain
- Where
- Minneapolis
- Age
- 18 years and over
- People
- 80
- Run by
- University of Minnesota
See details and how to joinNCT07910396 - Phase 3Taking peopleA Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
- Where
- Flowood, Grand Rapids, Houston, Indianapolis, New York
- Age
- 12 years and over
- People
- 159 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT07656415 · EU 2026-526778-18-00 - Phase 1/2Taking peopleA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- Where
- Birmingham, Boston, Charlotte, Greenville, Houston, Miami, New York, Philadelphia, Providence
- Age
- 12 years to 55 years
- People
- 161 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06546670 · EU 2024-515696-35-00 - Phase 1/2Taking peopleRepeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
- Where
- Bethesda
- Age
- 2 years to 80 years
- People
- 32
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT04008368 - Phase 2Taking peopleAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- Where
- Valhalla
- Age
- 1 day to 30 years
- People
- 20
- Run by
- Mitchell Cairo
See details and how to joinNCT04099966 - No phaseTaking peopleTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
- Where
- Atlanta
- Age
- 7 years to 18 years
- People
- 20
- Run by
- Emory University
See details and how to joinNCT07090668 - Phase 1Taking peopleEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
- Where
- Bethesda
- Age
- 18 years to 90 years
- People
- 25
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT07566494 - Phase 1Taking peopleHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease
- Where
- Boston
- Age
- 13 years to 35 years
- People
- 5
- Run by
- Daniel Bauer
See details and how to joinNCT07708350 - Phase 1/2Taking peopleTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
- Where
- Davis, Los Angeles, Oakland
- Age
- 12 years to 35 years
- People
- 9
- Run by
- Mark Walters, MD
See details and how to joinNCT04774536 - No phaseTaking peopleVirtual Reality for SCD VOC
- Where
- Baltimore
- Age
- 18 years to 88 years
- People
- 50
- Run by
- University of Maryland, Baltimore
See details and how to joinNCT07674277 - Phase 1Taking peopleGene Editing For Sickle Cell Disease
- Where
- Memphis
- Age
- 18 years to 24 years
- People
- 25
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT06506461 - Phase 3Taking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Ann Arbor, Baltimore, Birmingham, Chicago, Clovis, Coral Springs, Flowood, Greenville, Houston, Indianapolis, Los Angeles, Memphis, Miami, Phoenix, Portland, Richmond, Shreveport, Staten Island, The Bronx, Washington D.C.
- Age
- 10 years to 65 years
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - No phaseNot yet taking people in United StatesSelf-administered Acupressure in Patients With Sickle Cell Disease
- Where
- Cincinnati, Irvine
- Age
- 18 years to 80 years
- People
- 300
- Run by
- University of Cincinnati
See details and how to joinNCT07875777 - Phase 1/2Taking peoplePartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- Where
- Bethesda
- Age
- 4 years to 65 years
- People
- 90
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT07599176 - No phaseTaking peoplePeer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Where
- Ann Arbor, Atlanta, Chicago, Durham, Greenville, Hartford, Los Angeles, Mobile, Newark, New York, Pittsburgh, Richmond, Rochester
- Age
- 16 years to 39 years
- People
- 390
- Run by
- University of Pittsburgh
See details and how to joinNCT06374238